TP53 and lymphoma: Clinically, ALRN-6924 was evaluated as monotherapy and in combination with cytarabine in patients with haematologic neoplasms (NCT02909972) and has advanced into a phase I/II clinical study in patients with advanced solid tumours or lymphomas retaining wild-type p53 (NCT02264613).